Merit Medical Systems (MMSI) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $0.19 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $0.17. The company posted revenue of $138.10 million in the period, compared to analysts expectations of $137.96 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.18 EPS.
Merit Medical Systems closed down -0.13 points or -0.65% at $19.76 with 3,07,089 shares getting traded on Wednesday. Post opening the session at $19.98, the shares hit an intraday low of $19.7 and an intraday high of $20.15 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Mar 8, 2016, Kent W Stanger (director) sold 5,000 shares at $19.34 per share price. According to the SEC, on Dec 17, 2015, Fred P Lampropoulos (President & CEO) sold 3,125 shares at $18.47 per share price. On Dec 11, 2015, A Scott Anderson (director) sold 10,600 shares at $18.45 per share price, according to the Form-4 filing with the securities and exchange commission.
Merit Medical Systems Inc. (Merit) is a designer developer manufacturer and marketer of medical devices used in an array of interventional and diagnostic procedures across the world. The Company operates in the diagnostic and interventional cardiology interventional radiology interventional gastroenterology interventional pulmonology thoracic surgery interventional nephrology vascular surgery oncology electrophysiology cardiac rhythm management and pain management markets. It operates in segments: cardiovascular and endoscopy. Its cardiovascular segment comprises cardiology and radiology devices which assist in diagnosing and treating coronary arterial disease peripheral vascular disease and other non-vascular diseases and includes the embolotherapeutic products. Its endoscopy segment comprises gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal tracheobronchial and biliary strictures caused by malignant tumors.